"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04390594","Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","SEN-CoV-Fadj","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + Azithromycin","SARS-CoV-2 viral load level|Vital status|Proportion of patients with serious adverse events reported during the clinical trial.|Length of hospitalization|Length of hospitalization in a resuscitation unit|Duration of oxygen therapy|Maximum quick SOFA (qSOFA) score during hospitalisation","Institut Pasteur de Dakar|Fann Hospital, Senegal|Ministry of Health, Senegal|Diamniadio Children Hospital, Senegal|Dalal Jamm Hospital, Senegal","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","258","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-002","June 1, 2020","December 1, 2020","June 1, 2021","May 15, 2020",,"May 27, 2020","Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal|Diamniadio Children Hospital, Diamniadio, Senegal|Dalal Jamm Hospital, Guédiawaye, Senegal",,"https://ClinicalTrials.gov/show/NCT04390594"
2,"NCT04321278","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)",,"Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine","Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype","Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","30155020.5.1001.0071","March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",,"May 27, 2020","Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil|Hospital e Clínica São Roque, Ipiaú, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil|Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil|Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil|Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil|Hospital Santa Paula, Passos, MG, Brazil|Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Adventista de Belém, Belém, Pará, Brazil|Hospital Adventista de Belem, Belem, PA, Brazil|Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil|Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil|Hospital São Lucas, Rio De Janeiro, RJ, Brazil|Hospital Maternidade PROMATER, Natal, RN, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil|Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Hospital Nereu Ramos, Florianópolis, SC, Brazil|Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital Municipal Sao Jose, Joinville, SC, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil|Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil|nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil|Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil|AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil|Casa de Saude Santa Marcelina, São Paulo, SP, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil|Hospital Moriah, São Paulo, SP, Brazil|Hospital Nove de Julho, São Paulo, SP, Brazil|Hospital Santa Paula, São Paulo, SP, Brazil|Hospital São Camilo Pompeia, São Paulo, SP, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital Vila Santa Catarina, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04321278"
3,"NCT04374903","Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients","COVID19-HOPE","Not yet recruiting","No Results Available","COVID-19 Patients","Drug: HCQ & AZ vs HCQ+SIR","Time to Clinical improvement (TTCI)|Clinical failure defined as death or need for Intubation and mechanical ventilation|Adverse effects|QT interval prolongation|Failure to continue assigned therapy|Time to viral clearance","King Hussein Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20 KHCC 74","May 1, 2020","August 1, 2020","September 1, 2020","May 5, 2020",,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04374903"
4,"NCT04345861","Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)","COVIDOC","Recruiting","No Results Available","Coronavirus Infection|Pneumonia, Viral","Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin","Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images","University Hospital, Montpellier","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RECHMPL20_168","April 11, 2020","September 6, 2020","April 6, 2021","April 15, 2020",,"April 24, 2020","Montpellier University hospital, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04345861"
5,"NCT04322123","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)","Coalition-I","Active, not recruiting","No Results Available","Coronavirus Infections","Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin","Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days","Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS","All","18 Years and older   (Adult, Older Adult)","Phase 3","630","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Brazil COVID Coalition I Trial","April 1, 2020","August 30, 2020","August 30, 2020","March 26, 2020",,"June 1, 2020","Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil",,"https://ClinicalTrials.gov/show/NCT04322123"
6,"NCT04349592","Qatar Prospective RCT Of Therapy Eliminating Covid Transmission","Q-PROTECT","Not yet recruiting","No Results Available","Covid19","Drug: Hydroxychloroquine + Azithromycin|Drug: Hydroxychloroquine + Placebo|Other: Placebo + Placebo","Proportion of virologically cured (no virus detected) cases at day 6|The dichotomous virologic shedding endpoint as assessed at two weeks after study entry|Quantitative viral load (assessed with each virology testing set)","Hamad Medical Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","456","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MRC-05-001","April 14, 2020","May 14, 2020","May 30, 2020","April 16, 2020",,"April 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04349592"
7,"NCT04355052","Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus","COSTA","Recruiting","No Results Available","COVID - 19","Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin","clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death","Sheba Medical Center","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7092-20-SMC","April 11, 2020","October 11, 2020","December 11, 2020","April 21, 2020",,"April 21, 2020","Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel",,"https://ClinicalTrials.gov/show/NCT04355052"
8,"NCT04358081","Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",,"Recruiting","No Results Available","Pneumonia","Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo","Percentage of participants who achieve clinical response|Percentage of Participants with Viral Clearance|Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","444","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CJWT629A12301","May 1, 2020","June 25, 2020","July 24, 2020","April 22, 2020",,"May 21, 2020","Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04358081"
9,"NCT04347031","A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19",,"Active, not recruiting","No Results Available","Pneumonia, Viral|Respiratory Failure","Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab","1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2","Burnasyan Federal Medical Biophysical Center","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FL-01/20","April 8, 2020","August 1, 2020","August 1, 2020","April 15, 2020",,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04347031"
10,"NCT04338698","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","PROTECT","Not yet recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin","Laboratory Result|Clinical Outcome","Shehnoor Azhar|Federal Task Force on Science & Technology notified by Government of Pakistan|University of Health Sciences Lahore","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12(06)/2016-Coord","April 7, 2020","September 1, 2020","November 30, 2020","April 8, 2020",,"April 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04338698"
11,"NCT04365231","Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial","HASCOPT","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients","Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit","Hospital St. Joseph, Marseille, France","Female","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HASCOPT2020","April 2020","June 2020","January 2021","April 28, 2020",,"April 28, 2020","Hopital Saint Joseph, Marseille, Paca, France",,"https://ClinicalTrials.gov/show/NCT04365231"
12,"NCT04329832","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","HAHPS","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score","Intermountain Health Care, Inc.|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051355","March 30, 2020","December 31, 2020","December 31, 2021","April 1, 2020",,"June 2, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04329832"
13,"NCT04371406","Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients","MG-COVID","Not yet recruiting","No Results Available","Covid-19","Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc","Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy (after day 2) at day 14|The rate of use of secondary antibiotic therapy (after day 2) at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","2770","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200447|2020-001702-35","May 2, 2020","August 2, 2020","September 2, 2020","May 1, 2020",,"May 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04371406"
14,"NCT04334382","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","HyAzOUT","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days","Intermountain Health Care, Inc.|University of Utah|Utah Department of Health","All","45 Years and older   (Adult, Older Adult)","Phase 3","1550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051360","April 2, 2020","December 31, 2020","December 31, 2021","April 6, 2020",,"April 9, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04334382"
15,"NCT04341870","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","CORIMUNO-VIRO","Suspended","No Results Available","COVID19|SARS-CoV-2 Infection","Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine","Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-3","April 11, 2020","May 8, 2020","August 2020","April 10, 2020",,"May 6, 2020","AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France|AP-HP Hôpital Beaujon, Clichy, France|AP-HP Hôpital Pitié Salpétrière, Paris, France|AP-HP Hôpital Saint Antoine, Paris, France",,"https://ClinicalTrials.gov/show/NCT04341870"
16,"NCT04348474","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19",,"Suspended","No Results Available","Covid-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity","Azidus Brasil","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIAPRE0420OR","April 20, 2020","June 30, 2020","July 31, 2020","April 16, 2020",,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04348474"
17,"NCT04336332","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19",,"Recruiting","No Results Available","SARS-CoV-2|COVID-19","Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate","Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","002011|Pro2020000712","April 1, 2020","April 30, 2021","April 30, 2021","April 7, 2020",,"May 8, 2020","Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04336332"
18,"NCT04405921","Hydroxychloroquine, Azithromycin in the Treatment of Covid-19","PACTT","Not yet recruiting","No Results Available","SARS-CoV-2 Pneumonia|COVID-19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG","Clinical recovery at day-14, from the start of treatment.|Viral Clearance via RT-PCR at day 5- 7-10 and day 14","Centre Hôpital Universitaire Farhat Hached","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","PACTT","July 2020","December 2020","March 2021","May 28, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04405921"
19,"NCT04346693","An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19",,"Active, not recruiting","No Results Available","Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study","Burnasyan Federal Medical Biophysical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAL-05-04-2020","April 8, 2020","December 2020","December 2020","April 15, 2020",,"May 27, 2020","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04346693"
20,"NCT04329572","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19",,"Suspended","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days","Azidus Brasil","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","400","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIAPRE0320OR","April 23, 2020","May 31, 2020","June 30, 2020","April 1, 2020",,"April 22, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04329572"
21,"NCT04359953","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19","COVID-Aging","Not yet recruiting","No Results Available","COVID-19 Infection","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan","Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants","University Hospital, Strasbourg, France","All","60 Years and older   (Adult, Older Adult)","Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7747","April 24, 2020","June 1, 2021","June 1, 2021","April 24, 2020",,"April 24, 2020","CHU de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04359953"
22,"NCT04358068","Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",,"Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin","Proportion of participants who died from any cause or were hospitalized|Proportion of participants who died from any cause|Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic|Proportion of participants who died from any cause or were hospitalized through the end of follow-up|Proportion of participants who prematurely discontinue study treatment due to an adverse event|Proportion of participants who had any cardiac adverse events|Duration of fever|Duration of symptoms associated with COVID-19 disease|Participant-specific area under the curve (AUC) of the symptom score associated with COVID-19 disease over time|Time to self-reported return to usual (pre-COVID) health.|SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset|SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset","National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD","All","18 Years and older   (Adult, Older Adult)","Phase 2","2000","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACTG A5395|38720","May 1, 2020","October 9, 2020","March 5, 2021","April 22, 2020",,"June 9, 2020","Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|University of Southern California CRS, Los Angeles, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Case Clinical Research Site, Cleveland, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04358068"
23,"NCT04341207","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","ONCOVID","Recruiting","No Results Available","Cancer & COVID 19","Drug: Hydroxychloroquine|Drug: Azithromycin","Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001250-21|2020/3078","April 3, 2020","April 2022","April 2022","April 10, 2020",,"April 10, 2020","Gustave Roussy, Villejuif, Val De Marne, France",,"https://ClinicalTrials.gov/show/NCT04341207"
24,"NCT04347512","EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","TEACHCOVID","Withdrawn","No Results Available","Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm","Rate of patients reaching a significant hypoxemia, in each arms.","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7783","June 2, 2020","June 2, 2020","June 2, 2020","April 15, 2020",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04347512"
25,"NCT04392128","Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)","HYACINTHE","Not yet recruiting","No Results Available","COVID19|Hematologic Malignancy","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule","Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|Clinical evolution|Proportion of patients progressing to a severe form|Mortality|Evaluation of viral load drop|Tolerance of study treatment|Evaluation of the seroconversion|NK immunological study|Hospitalisation duration|Impact of the study treatment on the treatment of the hematological disease|Monitoring of the QT space|Dosage of residual concentration of azithromycine and hydroxychloroquine.|T immunological study","Institut de Cancerologie Strasbourg Europe","All","18 Years and older   (Adult, Older Adult)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-005|2020-002002-45","May 12, 2020","December 31, 2020","January 31, 2021","May 18, 2020",,"May 20, 2020","Institut de Cancérologie Strasbourg Europe, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04392128"
26,"NCT04370782","Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline","Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms","St. Francis Hospital, New York","All","30 Years and older   (Adult, Older Adult)","Phase 4","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-21","April 28, 2020","September 30, 2020","December 31, 2020","May 1, 2020",,"May 18, 2020","St Francis Hospital, Roslyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT04370782"
27,"NCT04332094","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","TOCOVID","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIBSP-COV-2020-23","April 2, 2020","September 2020","October 2020","April 2, 2020",,"April 7, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04332094"
28,"NCT04335552","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",,"Recruiting","No Results Available","SARS-CoV-2","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events","Duke University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00105339","April 17, 2020","August 1, 2020","August 1, 2020","April 6, 2020",,"April 24, 2020","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04335552"
29,"NCT04359316","Azithromycin in Hospitalized COVID-19 Patients","AIC","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Azithromycin in COVID-19","April 20, 2020","May 3, 2020","May 5, 2020","April 24, 2020",,"April 24, 2020","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04359316"
30,"NCT04328272","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Covid","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers","Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad","All","18 Years to 50 Years   (Adult)","Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Ath/ct101/22/3","March 28, 2020","May 28, 2020","June 28, 2020","March 31, 2020",,"April 2, 2020","Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",,"https://ClinicalTrials.gov/show/NCT04328272"
31,"NCT04374552","Asymptomatic COVID-19 Trial","ACT","Not yet recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo","The primary outcome is the rate of decline in viral load over the 10 days after randomization","Rutgers, The State University of New Jersey","All","20 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro2020000872","May 5, 2020","November 2020","April 2021","May 5, 2020",,"May 5, 2020","Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04374552"
32,"NCT04354597","Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients","MOPHYDA","Not yet recruiting","No Results Available","COVID-19","Drug: HCQ & AZ","Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate","King Hussein Cancer Center","All","25 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20 KHCC 67","May 1, 2020","August 15, 2020","October 15, 2020","April 21, 2020",,"May 5, 2020","King Hussein Cancer Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04354597"
33,"NCT04344379","Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","PREP-COVID","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo","To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","APHP200386|2020-001273-73","April 15, 2020","July 31, 2020","August 31, 2020","April 14, 2020",,"April 24, 2020","Hopial Avicenne, Bobigny, France|Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France|Hôpital Saint Antoine, Paris, France|Hôpital Broca, Paris, France|Hôpital La Pitié-Salpétrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital européen Georges Pompidou, Paris, France|Hôpital Necker, Paris, France",,"https://ClinicalTrials.gov/show/NCT04344379"
34,"NCT04361461","Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)",,"Not yet recruiting","No Results Available","Coronavirus Infections|SARS-CoV 2|SARS (Severe Acute Respiratory Syndrome)|Pulmonary Disease","Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin","Individual response rate|All-cause mortality|Duration of mechanical ventilation|Proportion of patients which needed mechanical ventilation during study|World Health Organization (WHO) Ordinal scale|Duration of hospitalization|Rates of drug discontinuation","Apsen Farmaceutica S.A.|Hospital São Paulo","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APS001/2020","May 4, 2020","November 4, 2020","November 4, 2020","April 24, 2020",,"April 24, 2020","Apsen Farmacêutica S.A., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04361461"
35,"NCT04395768","International ALLIANCE Study of Therapies to Prevent Progression of COVID-19",,"Not yet recruiting","No Results Available","COVID19","Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12","Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support","National Institute of Integrative Medicine, Australia|Catholic Health Initiatives","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alliance-COVID19","May 25, 2020","May 31, 2021","December 31, 2021","May 20, 2020",,"May 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04395768"
36,"NCT04363203","VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)","VA-REACH","Active, not recruiting","No Results Available","SARS-CoV-2|COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet","Days to resolution of cough, fever and shortness of breath|Days to resolution of all COVID-19 symptoms|All cause hospitalization|All cause mortality|COVID-19 specific mortality|COVID-19 specific hospitalization","Salomeh Keyhani MD|San Francisco VA Health Care System","All","216 Months and older   (Adult, Older Adult)","Phase 3","300","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-30517","April 30, 2020","March 2021","August 2021","April 27, 2020",,"May 11, 2020","San Francisco VA, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04363203"
37,"NCT04374019","Novel Agents for Treatment of High-risk COVID-19 Positive Patients",,"Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate","Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Change in Clinical Status|Mortality|Rate of severe adverse events|Oxygen-free days|Ventilator-free days|Vasopressor-free days|ICU-free days|Hospital-free days|Patients meeting Hy's Law criteria|Liver Function|Heart Function","Susanne Arnold|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20-COVID-01-PMC","May 1, 2020","May 2021","May 2021","May 5, 2020",,"May 7, 2020","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT04374019"
38,"NCT04322396","Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19","ProPAC-COVID","Recruiting","No Results Available","Virus Diseases|Infection Viral|Corona Virus Infection","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","All","Child, Adult, Older Adult","Phase 2","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KronLungesyg_COVID_19_protokol","April 6, 2020","October 31, 2020","March 31, 2021","March 26, 2020",,"May 11, 2020","Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark",,"https://ClinicalTrials.gov/show/NCT04322396"
39,"NCT04344457","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement","Perseverance Research Center, LLC|Athena Medical Group","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIZ-PRC-COVID-19","April 16, 2020","June 20, 2020","September 30, 2020","April 14, 2020",,"April 30, 2020","Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04344457"
40,"NCT04344444","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease","RCT","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Most severe outcome","LCMC Health","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID 2020-001","April 10, 2020","April 10, 2021","December 10, 2021","April 14, 2020",,"April 14, 2020","University Medical Center New Orleans, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04344444"
41,"NCT04359095","Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment","Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection","Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia|Clínica Reina Sofía|Fundación Cardio Infantil|Hospital Universitario de Neiva","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","76968","May 11, 2020","October 11, 2020","October 31, 2020","April 24, 2020",,"April 24, 2020","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia",,"https://ClinicalTrials.gov/show/NCT04359095"
42,"NCT04373733","A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe","PIONEER","Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Other: Standard of care management","Time to improvement by two points on a seven-category ordinal scale|Clinical status on a seven-category ordinal scale (Day 7)|Clinical status on a seven-category ordinal scale (Day 14)|Overall survival|Time to improvement by two points on the NEWS score|Time to improvement by two points on the NEWS element score for temperature|Time to improvement by two points on the NEWS element score for heartrate|Time to improvement by two points on the NEWS element score for respiratory rate|Time to improvement by two points on the NEWS element score for oxygen saturation.|Admission to intensive care|Requirement for mechanical ventilation|Requirement for non-invasive ventilation, continuous positive airways pressure or high-flow oxygen|Incidence of bacterial or fungal infection|Incidence of adverse events not directly caused by COVID-19 infection.","Chelsea and Westminster NHS Foundation Trust|NEAT ID Foundation|FUJIFILM Toyama Chemical Co., Ltd.|Imperial College London|Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CW002|2020-001449-38","May 1, 2020","March 31, 2021","March 31, 2021","May 4, 2020",,"May 4, 2020","Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04373733"
43,"NCT04351919","Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)","COVID+PA","Not yet recruiting","No Results Available","Patients With COVID19","Drug: Hydroxychloroquine|Drug: Azithromycin","improvment or healing of clinical signs|Evolution of clinical signs","Abderrahmane Mami Hospital|Eshmoun Clinical Research Centre|Dacima Consulting","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECC2020-04","May 5, 2020","July 15, 2020","July 15, 2020","April 17, 2020",,"May 5, 2020","Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT04351919"
44,"NCT04339816","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial","AZIQUINE-ICU","Recruiting","No Results Available","COVID-19|Respiratory Failure","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo","Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90","Frantisek Duska, MD, PhD|Masaryk Hospital Usti nad Labem|University Hospital Pilsen|The Faculty Hospital Na Bulovce|St. Anne's University Hospital Brno, Czech Republic|University Hospital, Motol|General University Hospital, Prague|University Hospital Olomouc|Charles University, Czech Republic","All","18 Years and older   (Adult, Older Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","AZIQUINE-ICU-25032020|2020-001456-18","May 13, 2020","December 31, 2021","June 30, 2022","April 9, 2020",,"June 4, 2020","František Duška, Praha, Česká Republika, Czechia",,"https://ClinicalTrials.gov/show/NCT04339816"
45,"NCT04341727","Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","WU352","Suspended","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate","Hours to recovery|Time fever resolution","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202003188","April 4, 2020","April 1, 2021","August 1, 2021","April 10, 2020",,"June 4, 2020","Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04341727"
46,"NCT04383717","Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial",,"Not yet recruiting","No Results Available","Respiratory Tract Infections","Drug: Levamisole and isoprinosine|Drug: Azithromycin and hydroxychloroquine","COVID 19 induced fever in both groups|COVID 19 induced dyspnea in both groups|COVID 19 viral load in both groups|laboratory clearance in both groups: CRP in mg/dL","Cairo University","All","6 Years to 90 Years   (Child, Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Levamisole and isoprinosine","May 5, 2020","August 30, 2020","October 30, 2020","May 12, 2020",,"May 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04383717"
47,"NCT04411433","Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19",,"Recruiting","No Results Available","Sars-CoV2|COVID-19","Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin","Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oxymetry from baseline|Changes in fever from baseline","Ministry of Health, Turkey|Hacettepe University, Faculty of Medicine|Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization|Umraniye Education and Research Hospital|SB Istanbul Education and Research Hospital|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey|Tepecik Training and Research Hospital|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine|Ankara University|Ankara City Hospital Bilkent|Ankara Training and Research Hospital|Ege University Hospital (Application and Research Center)|Kocaeli Derince Education and Research Hospital|Istanbul University, Istanbul Faculty of Medicine|Kayseri City Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19-FAV","May 8, 2020","July 30, 2020","July 30, 2020","June 2, 2020",,"June 2, 2020","Hacettepe University, School of Medicine, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT04411433"
48,"NCT04334512","A Study of Quintuple Therapy to Treat COVID-19 Infection","HAZDpaC","Not yet recruiting","No Results Available","COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)","Phase 2","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRG-044","May 2020","May 2021","August 2021","April 6, 2020",,"May 12, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04334512"
49,"NCT04368351","Bacteriotherapy in the Treatment of COVID-19","BACT-ovid","Active, not recruiting","No Results Available","COVID|Pneumonia|Diarrhea","Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine","delta of time of disappearance of acute diarrhea|Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital","University of Roma La Sapienza","All","18 Years and older   (Adult, Older Adult)",,"70","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DPHID-UniRoma05","March 1, 2020","June 30, 2020","July 31, 2020","April 29, 2020",,"May 4, 2020","Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04368351"
50,"NCT04390152","Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19",,"Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome","Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)","Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between ""Sequential Organ Failure Assessment"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.","BioXcellerator|Clinical Somer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BIOXSOMCOV001","June 2020","November 2020","May 2021","May 15, 2020",,"May 19, 2020","Clinical Somer, Rionegro, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT04390152"
51,"NCT04363060","Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit","AziA","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate","Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion","Nantes University Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RC20_0168","April 30, 2020","July 30, 2020","July 30, 2020","April 27, 2020",,"April 29, 2020","Chu Angers, Angers, France|CHD Vendée, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT04363060"
52,"NCT04350281","Double Therapy With IFN-beta 1b and Hydroxychloroquine",,"Recruiting","No Results Available","COVID","Drug: Interferon Beta-1B|Drug: Hydroxychloroquine","Time to negative NPS viral load|Time to NEWS 0|Length of Hospitalisation|Time to negative viral load in all clinical samples|Adverse events|Mortality|Inflammatory markers changes","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW 20-211","April 9, 2020","March 31, 2022","July 31, 2022","April 17, 2020",,"April 17, 2020","The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04350281"
53,"NCT04342221","Hydroxychloroquine for COVID-19","COV-HCQ","Recruiting","No Results Available","COVID-19, Hydroxychloroquine Sulfate","Drug: Hydroxychloroquine Sulfate|Drug: Placebo","Effect of HCQ on in vivo viral clearance","University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COV-HCQ|2020-001224-33","March 29, 2020","March 2021","February 2022","April 10, 2020",,"April 10, 2020","Institute for Tropical Medicine, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT04342221"
54,"NCT04354428","Treatment for COVID-19 in High-Risk Adult Outpatients",,"Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid","Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|Rate of participant-reported adverse events","University of Washington|Bill and Melinda Gates Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","630","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STUDY00009878|INV-017062","April 16, 2020","July 2020","October 2020","April 21, 2020",,"May 28, 2020","Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04354428"
55,"NCT04418193","Patient Preference Trial for COVID-19 (PPT-COVID)","PPT-COVID","Recruiting","No Results Available","Coronavirus",,"Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the World Health Organisation (WHO) Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) Reverse Transcriptase (RT) - Polymerase Chain Reaction (PCR) on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older","Centre Hospitalier Princesse Grace","All","18 Years to 99 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Other","20-08","April 6, 2020","September 1, 2020","September 1, 2020","June 5, 2020",,"June 9, 2020","Centre Hospitalier Princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT04418193"
56,"NCT04343092","Efficacy of Ivermectin as Add on Therapy in COVID19 Patients",,"Completed","No Results Available","COVID 19","Drug: Ivermectin (IVM)","Number of cured patients|Mean time to cure of the covid 19 patients","University of Baghdad","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO20040001","April 18, 2020","May 31, 2020","June 1, 2020","April 13, 2020",,"June 5, 2020","General Directorate of Medical City, Bagdad, Baghdad, Iraq",,"https://ClinicalTrials.gov/show/NCT04343092"
57,"NCT04365582","OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome","OUTCOV","Not yet recruiting","No Results Available","COVID","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab","Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events","Groupe Hospitalier Paris Saint Joseph","All","50 Years and older   (Adult, Older Adult)","Phase 3","640","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OUTCOV","April 28, 2020","July 28, 2020","January 28, 2021","April 28, 2020",,"April 28, 2020","Hôpital Privé d'Antony, Antony, France|Hôpital Avicenne, Bobigny, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Institut Mutualiste Montsouris, Paris, France",,"https://ClinicalTrials.gov/show/NCT04365582"
58,"NCT04353245","Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System","PostCOVID19","Not yet recruiting","No Results Available","COVID19|Corona Virus Infection|Myocardial Injury|Pneumonia","Other: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM","Fibrosis|Ergospirometers","University of Sao Paulo General Hospital","All","18 Years and older   (Adult, Older Adult)",,"130","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","UAP107","June 1, 2020","September 30, 2021","September 30, 2021","April 20, 2020",,"April 20, 2020","Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04353245"
59,"NCT04366089","Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora","PROBIOZOVID","Recruiting","No Results Available","COVID|SARS-CoV 2|Pneumonia, Viral|Coronavirus Infection","Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine","Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital|delta in the value of interleukin (IL)-1|delta in the value of IL-6|delta in the value of IL-10|delta in the value of Tumor Necrosis Factor (TNF)-alpha|delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)|delta in the value of CD8+ CD38/ HLA-DR|delta in the value of fecal calprotectin|delta in the value of lipopolysaccharide (LPS)|delta in the value of zonulin|delta in the value of alpha1-antitrypsin","Roberto Poscia MD, PhD|Azienda Policlinico Umberto I","All","18 Years and older   (Adult, Older Adult)","Phase 2","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","110/2020","March 26, 2020","October 30, 2020","December 31, 2020","April 28, 2020",,"April 28, 2020","Francesco Pugliese, Rome, RM, Italy",,"https://ClinicalTrials.gov/show/NCT04366089"
60,"NCT04381936","Randomised Evaluation of COVID-19 Therapy","RECOVERY","Recruiting","No Results Available","Severe Acute Respiratory Syndrome","Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab","All-cause mortality|Duration of hospital stay|Need for (and duration of) ventilation|Composite endpoint of death or need for mechanical ventilation or ECMO","University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Clinical Trials Unit Support Funding","All","Child, Adult, Older Adult","Phase 2|Phase 3","12000","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NDPHRECOVERY|2020-001113-21|ISRCTN50189673","March 19, 2020","December 2020","June 2021","May 11, 2020",,"June 5, 2020","Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04381936"
61,"NCT04324463","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","ACT COVID19","Recruiting","No Results Available","Coronavirus|Severe Acute Respiratory Syndrome","Drug: Azithromycin|Drug: Hydoxychloroquine or Chloroquine|Drug: Interferon-Beta","Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality","Population Health Research Institute|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRI.ACT.COVID19","April 21, 2020","September 30, 2020","December 31, 2020","March 27, 2020",,"April 24, 2020","Hamilton Health Sciences, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04324463"
62,"NCT04398004","Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early","ACHIEVE","Recruiting","No Results Available","COVID-19|Virus Diseases|Corona Virus Infection","Drug: Clarithromycin","Clinical outcome negative for two parameters(hospital admission/disease progression)|At least 50% change of the score of respiratory symptoms from the baseline|Comparison of two parameters with historical comparators from Hellenic Sepsis Study Group Database|Comparison of the score of respiratory symptoms with historical comparators from Hellenic Sepsis Study Group Database|Clinical outcome negative for two parameters(hospital admission/disease progression) on day 4|At least 50% change of the score of respiratory symptoms from the baseline on day 4|Range of development of severe respiratory failure|Range of hospital readmission until day 14|Change of viral load in respiratory secretions from baseline on day 8|Change of function of monocytes at days 1 and 8|Change of function of Th1 cells at days 1 and 8|Change of function of Th2 cells at days 1 and 8|Change of serum interleukin-6 (IL-6) cytokine levels between days 1 and 8|Change of serum interleukin-8 (IL-8) cytokine levels between days 1 and 8|Change of serum human beta defensin-2 (hBD-2) between days 1 and 8|Change of cytokine levels interleukin-6 (IL-6) at the rhinopharynx between days 1,4 and 8|Change of interleukin-1 (IL-1) cytokine levels at the rhinopharynx between days 1,4 and 8|Change of the IL-10/TNFα ratio between days 1 and 8","Hellenic Institute for the Study of Sepsis","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ACHIEVE|2020-001882-36","May 6, 2020","May 6, 2022","May 6, 2022","May 21, 2020",,"May 26, 2020","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece",,"https://ClinicalTrials.gov/show/NCT04398004"
63,"NCT04323345","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus",,"Recruiting","No Results Available","COVID-19","Dietary Supplement: Natural Honey|Other: Standard Care","Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results","Misr University for Science and Technology","All","5 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MUST23032020","April 15, 2020","December 15, 2020","January 15, 2021","March 26, 2020",,"April 21, 2020","Mahmoud Tantawy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04323345"
